Leukemia News and Research

RSS

Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.

DOD awards grant to develop ‘lab-on-a-chip’ device for monitoring patients with severe brain injury

The US Department of Defense (DOD) has awarded a $5 million grant to The Feinstein Institute for Medical Research and the University of Cincinnati to further develop a "lab-on-a-chip" device used for monitoring patients suffering from severe brain injury.

19 Oct 2010

UCB presents P3, P4 clinical trial data for Crohn's disease at ACG Scientific Meeting

Findings from the PRECiSE 3 (P3) open label extension study for Cimzia, demonstrating the longest continuously running maintenance trial for an anti-TNF in Crohn's disease, will be exhibited at the 2010 Annual Scientific Meeting of the American College of Gastroenterology (ACG), taking place in San Antonio from October 15 – 20. Additionally, long-term efficacy data from the PRECiSE 4 (P4) clinical trial also will be presented at the meeting.

19 Oct 2010

ACG meeting to exhibit Cimzia data for Crohn's disease treatment

Studies and analyses of the Crohn's disease (CD) treatment Cimzia (certolizumab pegol) will be exhibited at the 2010 Annual Scientific Meeting of the American College of Gastroenterology, taking place in San Antonio from October 15 – 20.

18 Oct 2010

Bristol-Myers, Otsuka launch My SPRYCEL Support program to assist patients with CML

Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced the launch of My SPRYCEL (dasatinib) Support, a useful resource to assist adult patients with chronic myeloid leukemia (CML) who are taking SPRYCEL.

15 Oct 2010

EntreMed receives letter from NASDAQ Stock Market

EntreMed, Inc. a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today announced that it has received a letter from the NASDAQ Stock Market indicating that it has regained compliance with the minimum $35 million Market Value of Listed Securities requirement for continued listing on the NASDAQ Capital Market as set forth in NASDAQ Marketplace Rule 5550(b)(2).

15 Oct 2010

New development of genetic tool to speed discovery of novel genes involved in cancer

Researchers have developed a genetic tool in mice to speed the discovery of novel genes involved in cancer. The system - called PiggyBac - has already been used by the team to identify novel candidate cancer-causing genes.

15 Oct 2010

ARTS protein increases apoptosis mechanism to balance stem cells' regenerative power: Research

Stem cells, the prodigious precursors of all the tissues in our body, can make almost anything, given the right circumstances. Including, unfortunately, cancer. Now research from Rockefeller University shows that having too many stem cells, or stem cells that live for too long, can increase the odds of developing cancer.

15 Oct 2010

First national educational conference on Graft vs. Host Disease

The Case Comprehensive Cancer Center, together with the Meredith A. Cowden Foundation, will bring the first national educational conference on Graft vs. Host Disease (GvHD) to Cleveland on Thursday, Nov. 4, 8 a.m. to 6 p.m., at Corporate College East, 4400 Richmond Road, Warrenville Hts. GvHD is a life-threatening complication experienced by an estimated 60 percent of all leukemia and other blood cancer patients following bone marrow transplantation. There is currently no cure.

14 Oct 2010

Scientists unveil quality control mechanism of immune system to destroy pathogens

An Australian team of scientists has uncovered a quality control mechanism that must take place for our immune system to subsequently effectively destroy harmful viruses and bacteria.

14 Oct 2010

New evidence supports possible link between XMRV and prostate cancer

Xenotropic murine leukemia virus-related virus (XMRV) has been the subject of many studies since its discovery in 2006, but conflicting reports have created an unclear picture of XMRV's role in human disease. In three recent studies published in the November 15 issue of The Journal of Infectious Diseases, now available online, the evidence supports a possible link between XMRV and prostate cancer but not other links involving chronic fatigue syndrome, HIV infection, or hepatitis C virus (HCV) infection.

13 Oct 2010

Micromet to initiate MEDI-565 Phase 1 trial in patients with advanced gastrointestinal cancer

Micromet, Inc. today announced that its licensee for MT111, MedImmune, plans to initiate a Phase 1 trial in patients with advanced gastrointestinal cancers based on an investigational new drug (IND) application recently accepted by the U.S. Food and Drug Administration (FDA).

11 Oct 2010

Obesity can accelerate progression of acute lymphoblastic leukemia: Study

The first study to demonstrate that obesity can directly accelerate the progression of acute lymphoblastic leukemia (ALL) has been conducted at The Saban Research Institute of Childrens Hospital Los Angeles and was published in Cancer Prevention Research, on October 5, 2010.

11 Oct 2010

Cincinnati Children's Hospital Medical Center named Centers of Excellence for Molecular Hematology

Cincinnati Children's Hospital Medical Center has been named one of five national Centers of Excellence for Molecular Hematology to find new gene and cell therapies for inherited diseases affecting blood cells.

8 Oct 2010

University of Colorado receives $6.3 million for umbilical cord blood bank

The University of Colorado Cord Blood Bank, a component of ClinImmune Labs and the University of Colorado School of Medicine, has been awarded $6.3 million to collect and bank umbilical cord blood, with an emphasis on donors from minority groups.

8 Oct 2010

Cyclacel announces completion of private placement sale

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, announced today that it consummated its previously announced private placement to sell approximately $15.2 million of its units to several institutional investors, including the Special Situations Funds, for net proceeds of approximately $14.1 million after the deduction of offering expenses.

7 Oct 2010

Cepheid collaborates with Novartis to commercialize BCR-ABL monitoring test

Cepheid today announced an exclusive collaboration with Novartis for the commercialization of a test for monitoring the BCR-ABL gene transcript in peripheral blood specimens from patients diagnosed with Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML). Together with other lab tests, monitoring levels of BCR-ABL transcripts in Ph+ CML patients will aid in patient management.

7 Oct 2010

Study on B-cell receptors may help develop new treatment strategies for leukaemia

In order to track down pathogens and render them harmless, the immune system must be able to recognize myriad different foreign substances and react to them. Scientists at the Max Planck Institute of Immunobiology and the Centre for Biological Signalling Studies BIOSS at the University of Freiburg have discovered how the immune system's B-cells can be activated by numerous substances from our environment.

7 Oct 2010

American Cancer Society awards 94 national research, training grants to 70 institutions nationwide

The American Cancer Society, the largest non-government, not-for-profit funding source of cancer research in the United States, has awarded 94 national research and training grants totaling $46,633,000 to 70 institutions nationwide in the first of two grants cycles for 2011.

7 Oct 2010

Onconova announces agreement with FDA for Estybon- MDS Phase 3 trial

Onconova Therapeutics, Inc. announced agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) for the design of a pivotal Phase 3 trial for Estybon- (ON 01910.Na) as monotherapy in patients with myelodysplastic syndromes (MDS), diseases affecting the production of healthy blood cells in the bone marrow.

5 Oct 2010

X-rays increase risk of developing childhood leukemia

Diagnostic X-rays may increase the risk of developing childhood leukemia, according to a new study by researchers at the University of California, Berkeley's School of Public Health.

4 Oct 2010

Leukemia News and Research

Further Reading

DOD awards grant to develop ‘lab-on-a-chip’ device for monitoring patients with severe brain injury

UCB presents P3, P4 clinical trial data for Crohn's disease at ACG Scientific Meeting

ACG meeting to exhibit Cimzia data for Crohn's disease treatment

Bristol-Myers, Otsuka launch My SPRYCEL Support program to assist patients with CML

EntreMed receives letter from NASDAQ Stock Market

New development of genetic tool to speed discovery of novel genes involved in cancer

ARTS protein increases apoptosis mechanism to balance stem cells' regenerative power: Research

First national educational conference on Graft vs. Host Disease

Scientists unveil quality control mechanism of immune system to destroy pathogens

New evidence supports possible link between XMRV and prostate cancer

Micromet to initiate MEDI-565 Phase 1 trial in patients with advanced gastrointestinal cancer

Obesity can accelerate progression of acute lymphoblastic leukemia: Study

Cincinnati Children's Hospital Medical Center named Centers of Excellence for Molecular Hematology

University of Colorado receives $6.3 million for umbilical cord blood bank

Cyclacel announces completion of private placement sale

Cepheid collaborates with Novartis to commercialize BCR-ABL monitoring test

Study on B-cell receptors may help develop new treatment strategies for leukaemia

American Cancer Society awards 94 national research, training grants to 70 institutions nationwide

Onconova announces agreement with FDA for Estybon- MDS Phase 3 trial

X-rays increase risk of developing childhood leukemia

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News